Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 22 May 2014
The US Food and Drug Administration (FDA) has announced the release of a final document intended to instruct sponsors, clinical investigators and institutional review boards (IRB) about how to transfer the oversight of clinical trials to a new IRB.
The guidance, Considerations When Transferring Clinical Investigation Oversight to Another Institutional Review Board, was first released in draft form in June 2012 by FDA and the US Department of Health and Human Services’ Office for Human Research Protections (OHRP), both of which oversee clinical trials in the US. (The difference: FDA oversees private clinical trials, while OHRP oversees government-run clinical trials).
The guidance contained a recommended eight-step process for transferring an IRB:
FDA notes in a 22 May 2014 Federal Register announcement that the guidance document has largely been left as-is, but contains a few changes.
In particular, new IRBs are now supposed to notify the sponsor of any decisions to suspend or terminate study approval. FDA also modified one section to recommend the use of a letter "to provide currently enrolled subjects with any changes in contact information," commonly used to report injuries or inquire about subject rights.
Other changes were largely editorial in nature or intended to clarify reporting requirements, FDA said.
Federal Register Announcement
Tags: US, FDA, Guidance, IRB, Clinical Trials, Institutional Review Board, Clinical Investigator